0947 ET - While D. Boral Capital says Invivyd's guidance didn't include the potential expansion of its Pemgarda drug use, analyst Jason Kolbert says it shows the challenges in securing approvals for COVID-19 therapeutics and reinforces the importance of pipeline diversification to sustain long-term growth. Pemgarda is a monoclonal antibody medication authorized for the pre-exposure prophylaxis of COVID‑19. Kolbert says Invivyd remains engaged with the FDA in pursuit of a regulatory pathway for its medication while preparing to provide additional data and regulatory correspondence to underscore its position. Invivyd tumbles 27% to $1.30. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
February 24, 2025 09:48 ET (14:48 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。